Clinical Amyloid Imaging.

Area of Science:

• Neurology
• Nuclear Medicine
• Radiology

Background:

• Alzheimer's disease (AD) is characterized by amyloid plaques and neurofibrillary tangles.
• Amyloid PET imaging utilizes newly approved radiotracers for neurodegenerative disorder evaluation.
• This imaging modality offers significant diagnostic and prognostic insights.

Purpose of the Study:

• To summarize the current understanding and clinical utility of amyloid PET imaging.
• To outline the appropriate use criteria for amyloid PET in diagnosing cognitive impairment.
• To highlight the role of amyloid PET in ongoing research and therapeutic trials for AD.

Main Methods:

• Review of clinical applications and research findings on amyloid PET imaging.
• Description of appropriate use criteria established by expert task forces.
• Mention of large-scale studies like the IDEAS study evaluating clinical impact.

Main Results:

• Amyloid PET imaging is valuable for diagnosing uncertain AD, unexplained MCI, and early-onset dementia.
• Ongoing studies assess its prognostic value and impact on patient management and outcomes.
• The modality is crucial for evaluating AD disease-modifying therapies.

Conclusions:

• Amyloid PET imaging is an essential tool in the diagnosis and management of neurodegenerative disorders.
• Its appropriate use, guided by established criteria, enhances diagnostic accuracy and patient care.
• Continued research will further define its role alongside other assessment techniques.